---
handoff_id: "CR163-CP2-META-PM-RETURN-SUMMARY"
cr_id: "CR-163"
from_agent: "meta-pm"
to_agent: "host-orchestrator"
phase: "requirement-clarification"
checkpoint: "CP1/CP2"
status: "returned-confirmed-ready-for-host-cp2-precheck"
created_at: "2026-07-11T11:50:00+08:00"
formal_cp2_gate_opened: false
ready_for_design: false
cp1_decision: "PASS"
cp2_status: "READY_FOR_HOST_CP2_PRECHECK_FORMAL_GATE_NOT_OPENED"
---

# CR163 CP2 Meta-PM Return Summary

## Outcome

CR163 的八份产品基线已增量更新，既有 CR157-CR162 条目与修订历史均保留。CP1 use-case completeness 通过。用户随后明确确认 SGQ-CR163-001..004 全部 option A；discussion 已完成。meta-pm 未打开 formal CP2，host-orchestrator 现在可以准备 CP2 precheck 与 Decision Brief。

## Frozen-Inventory Recommendation

仓库事实支持两个实际 strategy-candidate producer chains、四个 P0 instrumentation mappings：

1. `scripts/research/run_multifactor_strategy_research.py::main` → legacy Stage 3 wrapper → `engine.mature_multifactor_research.run_stage3_mature_multifactor_research`。
2. `engine.mature_multifactor_research.build_strategy_candidate`（链 1 的 direct hook）。
3. `scripts/legacy/research/run_multifactor_strategy_candidates.py` → `engine.multifactor_strategy_candidates.run_strategy_research`。
4. `engine.multifactor_strategy_candidates.build_strategy_candidates`（链 3 的 direct hook）。

确认后的 P0 coverage 定义为 **2 条去重 producer chains / 4 个 instrumentation mappings（CPI-CR163-001..004 4/4）**；wrapper 与 direct hook 按 stable trial identity 归属于同一 chain，不重复增加 raw trial count。

明确 excluded / N/A：

- `engine.anomaly_discovery.run_anomaly_discovery`：factor/anomaly discovery，不是 strategy-admission candidate family。
- `engine.mature_multifactor_framework.build_project_strategy_candidate_from_cr039`：归一化既有 candidate 的 compatibility adapter，不发起 trial。
- CR151 statistical gate、cross-strategy reliability、admission package：consumer integration surfaces，不生产 candidate。
- `BacktestRunSpec` 与 single-run `ExperimentManifest`：身份/单次 run contract，通过 refs 连接 family，但不替代 family lifecycle。
- UC-59 ML / UC-60 event：当前只有 fixture/static adapter compatibility；没有可合法声明为已 instrumented 的 real runner。

## Product Baseline Added

- 1 个 CR163 use case：`UC-58-CR163`。
- 8 个 P0 requirements：`REQ-CR163-001..008`。
- 12 个 P0 engineering scenarios：pre-search、append-only、seal、missing、duplicate conflict、retry/seed、effective unavailable、failed/cancelled/excluded、supersession、tamper、permission、CR155 regression。
- 12/12 TEST-MATRIX planned mappings。
- 5 个 outcome-oriented candidate Stories：S01 contract+validator、S02 recorder+seal+hash、S03 两条 producer chains / CPI-CR163-001..004 4/4 instrumentation、S04 existing admission integration、S05 integrity/recovery/tamper/CR155 regression。Story 数仍为五个；它们不是正式 Story decomposition，未修改 `DEVELOPMENT-PLAN`。
- 6 个 MVP scope items、5 个 release slices 与 3 个 deferred items。
- `FU-CR161-001` 已在 backlog 中标记为 promoted/active `CR-163`；`FU-CR161-002..006` 保持 candidate。

## Recommended CP2 Semantics

- family 必须在 first trial 前 declared；post-hoc declaration blocked。
- stable trial identity 区分参数/seed；retry 产生 distinct attempt，不增加 raw trial count。
- failed、cancelled、excluded trial 保留并计入 declared family；selection 不得缩小历史 family。
- `raw_trial_count = count(distinct stable_trial_id)`；duplicate delivery 仅在 identity+content 完全相同时幂等。
- seal 使用规范化内容和确定性排序；sealed version immutable；纠错只允许 append correction + superseding version。
- `ExperimentManifest` 保持 single-run object；family lineage 是独立 lifecycle，通过 `run_id` / `experiment_id` / artifact refs 关联。
- availability 维持 `present / typed_unavailable / not_applicable_with_reason / blocked`，不新建并行 gate。
- `effective_trial_count` 在 CR163 继续 `typed_unavailable`，ref 与 method 为空。
- 未来原生 instrumented run 只有在 seal、completeness、reference-integrity、count 和 tamper validation 全 PASS 后，`ExperimentFamilyManifest` 才可 `present`；未 instrumented path 保持 `typed_unavailable`；invalid/tampered lineage 为 `blocked`。
- CR163 只使 C1 raw-lineage input-ready；缺少 p-values、effective-trial method 与 statistical producer，因此不使 C1 computable。
- CR155 保持 blocked；不进行 historical lineage reconstruction。

## SGQ Confirmation Result

详见 `process/discussions/CP2-CR163-SCENARIO-DISCUSSION-LOG.md` 和 `process/checks/CP2-CR163-DISCUSSION-CHECKPOINT.json`。用户已明确确认四项均选择 A：

| Question | Confirmed option | Normalized result | Status |
|---|---|---|---|
| SGQ-CR163-001 frozen producer inventory | A | 2 deduplicated chains / 4 mappings；excluded/N/A 不变。 | confirmed |
| SGQ-CR163-002 count semantics | A | retry=attempt、seed/parameter=trial、failed/cancelled/excluded 保留并计数。 | confirmed |
| SGQ-CR163-003 effective count boundary | A | effective count unavailable；C1 raw-lineage input-ready only。 | confirmed |
| SGQ-CR163-004 seal correction | A | immutable sealed version + append-only supersession。 | confirmed |

所有四项现均为 `blocking=false`、`status=confirmed`。discussion checkpoint 已完成；本 agent 未创建正式 CP2 checkpoint/result、未发起人工 gate。

## Scope-Impact Conclusion

- Scope adjustment：`none`。没有新增能力、入口类别、runtime/data 权限或 statistical computation。
- Plan normalization：`CR163-S03` 必须在一个既有 Story 内覆盖两条 producer chains 与 CPI-CR163-001..004 全部 mappings；五 Story 数量不变。
- Availability normalization：present / typed_unavailable / blocked 的适用条件已在 use case、requirements、scenarios、matrix 和 MVP 中统一。
- Downstream boundary：CP3 仍负责最终 object/type/artifact architecture；CP5 前不得实现。

### SGQ Confirmation Normalization — Exact Changed Files

本次用户确认回填仅修改以下 11 个文件；CP1 result 未重写，未创建 CP2 checkpoint/result：

- `docs/product/USE-CASES.md`
- `docs/product/REQUIREMENTS.md`
- `docs/product/SCENARIOS.yaml`
- `docs/product/TEST-MATRIX.md`
- `docs/product/STORY-MAP.md`
- `docs/product/MVP-SCOPE.md`
- `docs/product/RELEASE-SLICES.md`
- `docs/product/BACKLOG.md`
- `process/checks/CP2-CR163-DISCUSSION-CHECKPOINT.json`
- `process/discussions/CP2-CR163-SCENARIO-DISCUSSION-LOG.md`
- `process/handoffs/CR163-CP2-META-PM-RETURN-SUMMARY.md`

## Authorization Boundary Preserved

本轮未读取 credentials，未运行真实 lake/NAS/provider/broker/trading/simulation/paper/live/external framework，未执行 remote write/publish/catalog pointer mutation，未重建 historical lineage，未计算 effective trial / FDR/BH / WRC/SPA / PBO/CSCV / DSR / walk-forward / TCA / capacity / alpha decay。未修改 source、tests、HLD/ADR、Story/LLD、`DEVELOPMENT-PLAN`、runtime state、git remote 或 release/publish state。

## Changed Files

产品基线（授权的 8/8）：

- `docs/product/USE-CASES.md`
- `docs/product/REQUIREMENTS.md`
- `docs/product/SCENARIOS.yaml`
- `docs/product/TEST-MATRIX.md`
- `docs/product/STORY-MAP.md`
- `docs/product/MVP-SCOPE.md`
- `docs/product/RELEASE-SLICES.md`
- `docs/product/BACKLOG.md`

CR163 过程产物（授权的 4/4）：

- `process/discussions/CP2-CR163-SCENARIO-DISCUSSION-LOG.md`
- `process/checks/CP2-CR163-DISCUSSION-CHECKPOINT.json`
- `process/checks/CP1-CR163-TRIAL-LINEAGE-INSTRUMENTATION-USE-CASE-COMPLETENESS.result.json`
- `process/handoffs/CR163-CP2-META-PM-RETURN-SUMMARY.md`

## Validation

- `uv run meta-flow workspace check --project-root .` → `process_link_health: ok`。
- `docs/product/SCENARIOS.yaml` YAML parse → 35 total scenarios，coverage summary 35；CR163 新增 12/12 P0。
- 两个 CR163 JSON artifacts 均通过 `python -m json.tool`。
- `uv run meta-flow cp result-check --result process/checks/CP1-CR163-TRIAL-LINEAGE-INSTRUMENTATION-USE-CASE-COMPLETENESS.result.json --project-root .` → `CP Result Check: OK`。
- `git diff --check` → PASS。

## Blocking Status and Next Route

- CP1：`PASS`。
- CP2 discussion：`completed`；四项 SGQ 已 confirmed-A。
- Formal CP2：未打开；状态为 `READY_FOR_HOST_CP2_PRECHECK_FORMAL_GATE_NOT_OPENED`。
- ready_for_design：`false`。
- 下一步：host-orchestrator 生成 CP2 precheck/Decision Brief → 仅在预检通过后打开正式 CP2 human gate。
